Pharmaceutical intermediates

Dabigatran etexilate mesylate Intermediates

3 pharmaceutical intermediates for Dabigatran etexilate mesylate. Indication: Venous Thromboembolism (VTE); Embolism; Stroke; Pulmonary Embolism; Venous Thrombosis.

提交项目 All intermediates

About Dabigatran etexilate mesylate

Originator: Boehringer Ingelheim
Indication: Venous Thromboembolism (VTE); Embolism; Stroke; Pulmonary Embolism; Venous Thrombosis
Approved Date: 06/21/2021
DS/DP: 09/07/2025

Available intermediates

3 intermediates currently listed for Dabigatran etexilate mesylate. Request specifications, documentation or a quotation for any item below.

Dabigatran etexilate mesylate intermediates
Product Name	CAS No.	Molecular Formula	Physical Properties
Dabigatran etexilate mesylate	872728-81-9	/	/
ethyl N-[3-amino-4-(methylamino)benzoyl]-N-pyridin-2-yl-beta-alaninate	212322-56-0	/	/
N-(4-cyanophenyl)-Glycine	42288-26-6	/	/

Other programs under D

Dabigatran Etexilate Dabrafenib Mesylate Dacomitinib Danicopan Dapagliflozin Daridorexant Hydrochloride Darolutamide Dasatinib Hydrate

Building toward Dabigatran etexilate mesylate?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →